This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Reasons to Hold Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cresco Labs Inc. (CRLBF) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cresco Labs Inc. (CRLBF) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Is Most-Watched Stock DaVita Inc. (DVA) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching DaVita HealthCare (DVA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia
by Zacks Equity Research
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
Why You Should Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
Why You Should Retain Inari Medical (NARI) Stock for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Shockwave Medical's (SWAV) Reducer Receives Positive Results
by Zacks Equity Research
Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes
by Zacks Equity Research
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
Thermo Fisher (TMO) Launches TSX Universal Series ULT Freezers
by Zacks Equity Research
Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.
Why the Market Dipped But DaVita HealthCare (DVA) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $133.73, denoting a +0.09% change from the preceding trading day.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Philips (PHG) Boosts Patient Monitoring With smartQare Deal
by Zacks Equity Research
Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.
BD's (BDX) Latest Product to Offer Wider Access to Researchers
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
by Zacks Equity Research
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
IM Cannabis (IMCC) Expands Business in Germany With New Alliance
by Zacks Equity Research
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
by Zacks Equity Research
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
by Zacks Equity Research
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
by Zacks Equity Research
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
Diagnosing the Economy Ahead of World Health Day: 6 Picks
by Sweta Killa
Similar to the six vital nutrients required for good health, we have examined the six pillars that support the economy and zeroed in on stocks that have a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a higher market cap in their respective sectors.